BMX-001 free base

Generic Name: BMX-001 free base

Drug Type: Small Molecule

Chemical Formula: C_₆₄H_₇₆MnN_₈O_₄

CAS Number: 1379866-50-8

Unique Ingredient Identifier: J06K64323R

Clinical Trials

BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

Phase 1

Not yet recruiting

Conditions: Ovarian Neoplasms
Endometrial Cancer, Endometrial Neoplasm

Interventions: Drug: BMX-001
Drug: Paclitaxel (Taxol)

First Posted Date: 2024-10-01

Last Posted Date: 2024-10-01

Lead Sponsor: BioMimetix JV, LLC

Target Recruit Count: 27

Registration Number: NCT06620029

Locations: 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States

Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001

Phase 2

Recruiting

Conditions: Rectal Cancer

Interventions: Drug: BMX-001

First Posted Date: 2022-02-24

Last Posted Date: 2024-07-09

Lead Sponsor: University of Nebraska

Target Recruit Count: 118

Registration Number: NCT05254327

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Trial of BMX-001 or Placebo in Head and Neck Cancer Patients

Phase 2

Withdrawn

Conditions: Head and Neck Cancer

Interventions: Drug: BMX-001
Radiation: Radiation Therapy
Other: Placebo
Drug: Cisplatin

First Posted Date: 2020-10-29

Last Posted Date: 2021-10-11

Lead Sponsor: BioMimetix JV, LLC

Registration Number: NCT04607642

A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

Phase 1

Terminated

Conditions: Multiple Brain Metastases

Interventions: Drug: BMX-001
Radiation: Whole Brain Radiation Therapy

First Posted Date: 2018-07-31

Last Posted Date: 2024-04-18

Lead Sponsor: BioMimetix JV, LLC

Target Recruit Count: 35

Registration Number: NCT03608020

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States

and more 1 locations

Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer

Phase 1

Active, not recruiting

Conditions: Radiation Exposure
Anal Cancer, Squamous Cell Carcinoma

Interventions: Drug: BMX-001

First Posted Date: 2017-12-29

Last Posted Date: 2025-05-21

Lead Sponsor: University of Nebraska

Target Recruit Count: 24

Registration Number: NCT03386500

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: BMX-001
Radiation: Radiation Therapy
Drug: Cisplatin

First Posted Date: 2016-12-13

Last Posted Date: 2023-03-15

Lead Sponsor: BioMimetix JV, LLC

Target Recruit Count: 29

Registration Number: NCT02990468

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
University of Florida- Gainesville, Gainesville, Florida, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 1 locations

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

Phase 2

Active, not recruiting

Conditions: Glioblastoma
High Grade Glioma
Astrocytoma, Grade III

Interventions: Drug: BMX-001
Radiation: Radiation Therapy
Drug: Temozolomide

First Posted Date: 2016-01-14

Last Posted Date: 2024-06-28

Lead Sponsor: BioMimetix JV, LLC

Target Recruit Count: 160

Registration Number: NCT02655601

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy